IFN alpha-IFNAR-IN-1

IFN alpha-IFNAR-IN-1 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Mar;13(13):e15546. [Abstract]

Customer Validation
Neuro‐2a cells were transfected with the indicated plasmids for 22 h, then treated with DMSO or 2 µM IFNAR1 inhibitor (IFN alpha‐IFNAR‐IN‐1 hydrochloride) for 16 h, and then infected with HSV‐1 (MOI = 0.2) in the presence of DMSO or the inhibitor for 40 h before virus titration.

IFN alpha-IFNAR-IN-1 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Sep;609(7928):785-792. [Abstract]

Customer Validation
Huh7 cells were pretreated with DMSO, 5 μM filgotinib, 5 μM ruxolitinib or 5 μM IFNα-IFNAR-IN-1 hydrochloride for 1 h and infected with MERS-CoV at a MOI of 1. After infection, the cells were incubated in media supplemented with DMSO, 5 μM filgotinib, 5 μM ruxolitinib or 5 μM IFNα-IFNAR-IN-1 hydrochloride in the presence of z-VEID-fmk as indicated. Cell lysates were collected at 24 hpi. MERS-CoV N gene copy number was quantified by RT–qPCR (n = 3).

IFN alpha-IFNAR-IN-1 purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2023 Jan:187:106615. [Abstract]

Customer Validation
The representative slit-lamp images of the Aire-KO corneas treated with IFNAR1-IN-1 (IFN alpha-IFNAR-IN-1 hydrochloride) (10 mg/mL; 6 µL, topical ocular administration, administered on post-injury days 0, 2, 4, and 6) on post-injured day 0, 1 and 2, respectively. The dynamic change of epithelial defect area in the injured Aire-KO corneas with different treatment determined by Image J software (n = 6).

IFN alpha-IFNAR-IN-1 purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2023 Jan:187:106615. [Abstract]

Customer Validation
IFN alpha-IFNAR-IN-1 hydrochloride (10 mg/mL; 6 µL, topical ocular administration, administered on post-injury days 0, 2, 4, and 6). The representative slit-lamp and OCT photographs of Aire-KO corneas with different treatments on postoperative day 7 and the corneal thickness with different groups measured using OCT on postoperative day 7 (n = 6).

IFN alpha-IFNAR-IN-1 purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2023 Jan:187:106615. [Abstract]

Customer Validation
Immunostaining analysis for K12 (red), K14 (red), K10 (green), and SPRR1B (green) in Aire-KO corneas with different groups (n = 6). Nuclei were counterstained with DAPI (blue). Scale bars: 30 µm. KO+ Control, the Aire-KO corneas treated with SBE-β-CD, KO+ IFNAR1-IN-1, the Aire-KO corneas administrated with IFNAR1-IN-1 (IFN alpha-IFNAR-IN-1 hydrochloride) (10 mg/mL; 6 µL, topical ocular administration, administered on post-injury days 0, 2, 4, and 6).

IFN alpha-IFNAR-IN-1 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2016 Jul 14;6:29665. [Abstract]

Customer Validation
PAMs are first pretreated with IFN-alpha-IFNAR-IN-1 or mock pretreated with medium containing DMSO for 2 h. The cells are then infected with the HP-PRRSV virus at an MOI of 5 or mock-infected with DMEM for 12 h and 16 h, respectively. The cell lysates are collected and analyzed by western blot. The fold change of SAMHD1 protein is expressed as densitometric units of the band normalized to the β-actin level relative to the uninfected control. The error bar represents standard deviation from three